Neurology

Back to articles

Topiramate Scores Well for Migraine Prevention

KEY POINT

The antiepileptic agent topiramate reduced migraine occurrence in 468 patients in a 26-week, randomized, double-blind, placebo-controlled trial, with benefits evident during the first month of therapy in those treated with daily doses of 100 mg or 200 mg of the drug.

SOURCES

Brandes JL et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965–73.

FDA MedWatch notice about metabolic acidosis with topiramate.